Literature DB >> 12594223

The oncogenic fusion protein-tyrosine kinase ZNF198/fibroblast growth factor receptor-1 has signaling function comparable with interleukin-6 cytokine receptors.

Heinz Baumann1, Padmaja Kunapuli, Erin Tracy, John K Cowell.   

Abstract

The reciprocal t(8;13) chromosome translocation results in a fusion gene (FUS) in which the N-terminal half of the zinc finger protein ZNF198 is combined with the cytoplasmic domain of the fibroblast growth factor receptor-1 (FGFR1). Expression of FUS is suggested to provide growth-promoting activity to myeloid cells similar to the activity of hematopoietic cytokine receptors. This study determined the specificity of FUS to activate signal transduction pathways. Because no tumor cell line expressing FUS was available, the mode of FUS action was identified in cells transiently and stably transfected with an expression vector for FUS. FUS acted as a constitutively active protein-tyrosine kinase and mediated phosphorylation of STAT1, 3, and 5 but not STAT4 and 6. The same specificity but lower activity was determined for normal FGFR1. STAT activation by FUS, similar to that by interleukin-6-type cytokines, promoted STAT-specific induction of genes. The functionality of FUS, as well as the relative recruitment of STAT isoforms, was determined by the dimerizing function of the zinc finger domain. Replacement of the ZNF198 portion by the Bcr portion as present in the t(8;22) translocation shifted the signaling toward a more prominent STAT5 activation. This study documents that both gene partners forming the fusion oncogene define the activity and the signaling specificity of the protein-tyrosine kinase of FGFR1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594223     DOI: 10.1074/jbc.M300018200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  miR-339 Promotes Development of Stem Cell Leukemia/Lymphoma Syndrome via Downregulation of the BCL2L11 and BAX Proapoptotic Genes.

Authors:  Tianxiang Hu; Yating Chong; Sumin Lu; Rebecca Wang; Haiyan Qin; Jeane Silva; Eiko Kitamura; Chang-Sheng Chang; LesleyAnn Hawthorn; John K Cowell
Journal:  Cancer Res       Date:  2018-05-07       Impact factor: 12.701

2.  Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease.

Authors:  Chitta S Kasyapa; Padmaja Kunapuli; Lesleyann Hawthorn; John K Cowell
Journal:  Blood       Date:  2006-01-12       Impact factor: 22.113

3.  Loss of the BCR-FGFR1 GEF Domain Suppresses RHOA Activation and Enhances B-Lymphomagenesis in Mice.

Authors:  Tianxiang Hu; Yating Chong; Sumin Lu; Haiyan Qin; Mingqiang Ren; Natasha M Savage; Chang-Sheng Chang; John K Cowell
Journal:  Cancer Res       Date:  2018-11-09       Impact factor: 12.701

4.  14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells.

Authors:  Shaozhong Dong; Sumin Kang; Ting-Lei Gu; Sean Kardar; Haian Fu; Sagar Lonial; Hanna Jean Khoury; Fadlo Khuri; Jing Chen
Journal:  Blood       Date:  2007-03-27       Impact factor: 22.113

5.  A model of BCR-FGFR1 driven human AML in immunocompromised mice.

Authors:  John K Cowell; Haiyan Qin; Chang-Sheng Chang; Eiko Kitamura; Mingqiang Ren
Journal:  Br J Haematol       Date:  2015-12-21       Impact factor: 6.998

6.  Phosphorylation of the SSBP2 and ABL proteins by the ZNF198-FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide-specific MS.

Authors:  Chitta Kasyapa; Ting-Lei Gu; Lalitha Nagarajan; Lalitha Natarajan; Roberto Polakiewicz; John K Cowell
Journal:  Proteomics       Date:  2009-08       Impact factor: 3.984

7.  Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase.

Authors:  Mingqiang Ren; Xiurong Li; John K Cowell
Journal:  Blood       Date:  2009-06-08       Impact factor: 22.113

8.  ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.

Authors:  Merrida A Childress; Stephen M Himmelberg; Huiqin Chen; Wanleng Deng; Michael A Davies; Christine M Lovly
Journal:  Mol Cancer Res       Date:  2018-07-12       Impact factor: 5.852

9.  Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice.

Authors:  Mingqiang Ren; Haiyan Qin; Qing Wu; Natasha M Savage; Tracy I George; John K Cowell
Journal:  Int J Cancer       Date:  2016-05-04       Impact factor: 7.396

10.  Mutations of the Transcriptional Corepressor ZMYM2 Cause Syndromic Urinary Tract Malformations.

Authors:  Dervla M Connaughton; Rufeng Dai; Danielle J Owen; Jonathan Marquez; Nina Mann; Adda L Graham-Paquin; Makiko Nakayama; Etienne Coyaud; Estelle M N Laurent; Jonathan R St-Germain; Lot Snijders Blok; Arianna Vino; Verena Klämbt; Konstantin Deutsch; Chen-Han Wilfred Wu; Caroline M Kolvenbach; Franziska Kause; Isabel Ottlewski; Ronen Schneider; Thomas M Kitzler; Amar J Majmundar; Florian Buerger; Ana C Onuchic-Whitford; Mao Youying; Amy Kolb; Daanya Salmanullah; Evan Chen; Amelie T van der Ven; Jia Rao; Hadas Ityel; Steve Seltzsam; Johanna M Rieke; Jing Chen; Asaf Vivante; Daw-Yang Hwang; Stefan Kohl; Gabriel C Dworschak; Tobias Hermle; Mariëlle Alders; Tobias Bartolomaeus; Stuart B Bauer; Michelle A Baum; Eva H Brilstra; Thomas D Challman; Jacob Zyskind; Carrie E Costin; Katrina M Dipple; Floor A Duijkers; Marcia Ferguson; David R Fitzpatrick; Roger Fick; Ian A Glass; Peter J Hulick; Antonie D Kline; Ilona Krey; Selvin Kumar; Weining Lu; Elysa J Marco; Ingrid M Wentzensen; Heather C Mefford; Konrad Platzer; Inna S Povolotskaya; Juliann M Savatt; Natalia V Shcherbakova; Prabha Senguttuvan; Audrey E Squire; Deborah R Stein; Isabelle Thiffault; Victoria Y Voinova; Michael J G Somers; Michael A Ferguson; Avram Z Traum; Ghaleb H Daouk; Ankana Daga; Nancy M Rodig; Paulien A Terhal; Ellen van Binsbergen; Loai A Eid; Velibor Tasic; Hila Milo Rasouly; Tze Y Lim; Dina F Ahram; Ali G Gharavi; Heiko M Reutter; Heidi L Rehm; Daniel G MacArthur; Monkol Lek; Kristen M Laricchia; Richard P Lifton; Hong Xu; Shrikant M Mane; Simone Sanna-Cherchi; Andrew D Sharrocks; Brian Raught; Simon E Fisher; Maxime Bouchard; Mustafa K Khokha; Shirlee Shril; Friedhelm Hildebrandt
Journal:  Am J Hum Genet       Date:  2020-09-04       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.